Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Status:
Recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
This study will be investigating the effect of latent tuberculosis infection (LTBI) treatment
on glucose tolerance and low-grade inflammation. Almost a century ago, researchers proposed
that diabetes (DM) was associated with increased risk of Tuberculosis infection (TB). A more
recent systematic review concluded that DM increases the relative risk for TB 3.1 times.
Reversely, TB may affect the glycaemic control; TB is in many cases a chronic infection
characterised by long term low-grade inflammation and weight loss, and persons with TB are
known to be at risk of hyperglycaemia and DM at time of diagnosis. A latent infection with
the m.tuberculosis bacteria is "silent" without symptoms.
1,7 billion have LTBI on a global scale. Event though the infected person does not experience
symptoms, increased background inflammation has been shown in LTBI patients in previous
studies. We also know that an increase in inflammatory markers precedes clinical development
of DM, and that subclinical inflammation contributes to insulin resistance. We hypothesise
that LTBI contributes to dysregulated glucose metabolism due to increased low-grade
inflammation, and that treatment will reduce low-grade inflammation and improve glucose
tolerance.